

# Daniel B Longley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8375753/publications.pdf>

Version: 2024-02-01

66  
papers

9,912  
citations

186265  
28  
h-index

118850  
62  
g-index

69  
all docs

69  
docs citations

69  
times ranked

18985  
citing authors

#	ARTICLE	IF	CITATIONS
1	FLINO: a new method for immunofluorescence bioimage normalization. <i>Bioinformatics</i> , 2022, 38, 520-526.	4.1	12
2	Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations. <i>Modern Pathology</i> , 2022, 35, 564-576.	5.5	12
3	An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. <i>Cell Death and Differentiation</i> , 2022, 29, 806-817.	11.2	15
4	Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 594-606.	4.1	1
5	Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers. <i>Molecular Cancer Research</i> , 2022, 20, 841-853.	3.4	3
6	The role of Ubiquitination in Apoptosis and Necroptosis. <i>Cell Death and Differentiation</i> , 2022, 29, 272-284.	11.2	72
7	Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors. <i>Nanoscale</i> , 2021, 13, 15010-15020.	5.6	5
8	Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer. <i>FEBS Journal</i> , 2021, 288, 5374-5388.	4.7	5
9	Therapeutics Targeting the Core Apoptotic Machinery. <i>Cancers</i> , 2021, 13, 2618.	3.7	14
10	Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1627-1639.	4.1	13
11	Antibody therapy in pancreatic cancer: mAb-ye weâ€™re onto something?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188557.	7.4	6
12	Patients with mesenchymal tumours and high <i>Fusobacteriales</i> prevalence have worse prognosis in colorectal cancer (CRC). <i>Gut</i> , 2021, , gutjnl-2021-325193.	12.1	23
13	TNF-Î± synergises with IFN-Î³ to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells. <i>Cell Death and Disease</i> , 2021, 12, 864.	6.3	54
14	TRAIL signaling promotes entosis in colorectal cancer. <i>Journal of Cell Biology</i> , 2021, 220, .	5.2	17
15	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17808-17819.	7.1	18
16	Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant. <i>Cell Death and Disease</i> , 2020, 11, 1020.	6.3	15
17	Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer. <i>Cell Death Discovery</i> , 2020, 6, 61.	4.7	18
18	Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 123, 1502-1512.	6.4	14

#	ARTICLE	IF	CITATIONS
19	RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. <i>Cell Death and Disease</i> , 2020, 11, 930.	6.3	12
20	Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells. <i>Nanoscale</i> , 2020, 12, 11647-11658.	5.6	16
21	DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. <i>Journal of Controlled Release</i> , 2020, 324, 610-619.	9.9	18
22	A revised model of <scp>TRAIL</scp> â€R2 <scp>DISC</scp> assembly explains how <scp>FLIP</scp> (L) can inhibit or promote apoptosis. <i>EMBO Reports</i> , 2020, 21, e49254.	4.5	36
23	The Multiple Roles of the IAP Super-family in cancer. , 2020, 214, 107610.		27
24	FLIP(L): the pseudoâ€caspase. <i>FEBS Journal</i> , 2020, 287, 4246-4260.	4.7	22
25	<i>Fusobacterium nucleatum</i> in the Colorectum and Its Association with Cancer Risk and Survival: A Systematic Review and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 539-548.	2.5	77
26	The SCFSkp2 ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L). <i>Cell Death and Differentiation</i> , 2020, 27, 2726-2741.	11.2	14
27	Heterogeneous responses to low level death receptor activation are explained by random molecular assembly of the Caspase-8 activation platform. <i>PLoS Computational Biology</i> , 2019, 15, e1007374.	3.2	9
28	A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-17.	2.1	4
29	Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. <i>Nanoscale</i> , 2019, 11, 20261-20273.	5.6	37
30	Abstract 382: Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP. <i>Cancer Research</i> , 2019, 79, 382-382.	0.9	2
31	Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711. <i>Cell Death and Differentiation</i> , 2018, 25, 1952-1966.	11.2	12
32	Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	3.0	45
33	Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists. <i>Cell Death and Disease</i> , 2018, 9, 1081.	6.3	14
34	<scp>FLIP</scp> as a therapeutic target in cancer. <i>FEBS Journal</i> , 2018, 285, 4104-4123.	4.7	54
35	Epithelialâ€toâ€mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition. <i>Journal of Pathology</i> , 2018, 246, 422-426.	4.5	25
36	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. <i>Nature Communications</i> , 2017, 8, 15657.	12.8	70

#	ARTICLE	IF	CITATIONS
37	IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer. <i>Cell Death Discovery</i> , 2017, 3, 17050.	4.7	5
38	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1200-1212.	7.0	21
39	Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 582-591.	3.4	35
40	Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4095-4104.	7.0	135
41	FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2432-2441.	4.1	21
42	PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. <i>Oncotarget</i> , 2016, 7, 7885-7898.	1.8	33
43	Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 36632-36644.	1.8	15
44	Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11592-11592.	1.6	0
45	HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. <i>Clinical Cancer Research</i> , 2015, 21, 3230-3240.	7.0	53
46	Molecular classification of the invasive front in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3573-3573.	1.6	0
47	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. <i>Cell Reports</i> , 2014, 7, 1940-1955.	6.4	90
48	AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 164-175.	7.0	95
49	Efficient Drug Delivery and Induction of Apoptosis in Colorectal Tumors Using a Death Receptor 5-Targeted Nanomedicine. <i>Molecular Therapy</i> , 2014, 22, 2083-2092.	8.2	37
50	Enhanced Antitumor Activity of the Photosensitizer meso-Tetra(N-methyl-4-pyridyl) Porphine Tetra Tosylate through Encapsulation in Antibody-Targeted Chitosan/Alginate Nanoparticles. <i>Biomacromolecules</i> , 2013, 14, 302-310.	5.4	72
51	Cancer drug resistance: an evolving paradigm. <i>Nature Reviews Cancer</i> , 2013, 13, 714-726.	28.4	3,667
52	Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 188-198.	2.5	39
53	Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor-Targeted Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 3822-3833.	7.0	53
54	A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 119-131.	4.1	27

#	ARTICLE	IF	CITATIONS
55	Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. <i>European Journal of Cancer</i> , 2012, 48, 1096-1107.	2.8	39
56	Conatumumab (AMC 655) coated nanoparticles for targeted pro-apoptotic drug delivery. <i>Biomaterials</i> , 2011, 32, 8645-8653.	11.4	62
57	In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 1435-1443.	4.9	15
58	Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 3442-3451.	7.0	70
59	Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2649-2661.	4.1	86
60	Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1544-1551.	4.1	44
61	Molecular mechanisms of drug resistance in acute myeloid leukaemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 363-377.	3.3	15
62	c-FLIP: A Key Regulator of Colorectal Cancer Cell Death. <i>Cancer Research</i> , 2007, 67, 5754-5762.	0.9	110
63	Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1766, 184-196.	7.4	106
64	Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 2026-2036.	4.1	140
65	5-Fluorouracil: mechanisms of action and clinical strategies. <i>Nature Reviews Cancer</i> , 2003, 3, 330-338.	28.4	4,015
66	Apoptotic and Necroptotic Mediators are Differentially Expressed in Mucinous and Non-Mucinous Colorectal Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0